GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » EPS (Basic)
中文

Cellectar Biosciences (Cellectar Biosciences) EPS (Basic)

: $-3.10 (TTM As of Dec. 2023)
View and export this data going back to 2005. Start your Free Trial

Cellectar Biosciences's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-0.40. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.10.

Cellectar Biosciences's EPS (Diluted) for the three months ended in Dec. 2023 was $-0.40. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.10.

Cellectar Biosciences's EPS without NRI for the three months ended in Dec. 2023 was $-0.73. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -3.08.

During the past 3 years, the average EPS without NRI Growth Rate was 25.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 41.10% per year. During the past 10 years, the average EPS without NRI Growth Rate was 54.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Cellectar Biosciences's highest 3-Year average EPS without NRI Growth Rate was 65.00% per year. The lowest was -185.80% per year. And the median was 38.85% per year.


Cellectar Biosciences EPS (Basic) Historical Data

The historical data trend for Cellectar Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -18.40 -7.60 -4.35 -4.05 -3.11

Cellectar Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.55 -0.76 -0.73 -1.21 -0.40

Cellectar Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Cellectar Biosciences's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-37.983-0)/12.222
=-3.11

Cellectar Biosciences's Basic EPS for the quarter that ended in Dec. 2023 is calculated as

Basic EPS (Q: Dec. 2023 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-7.449-0)/15.055
=-0.49

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectar Biosciences  (NAS:CLRB) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Cellectar Biosciences EPS (Basic) Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences (Cellectar Biosciences) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Executives
Andrei Shustov officer: Senior Vice President, Medical 7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea officer: Chief Commercial Officer 7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean officer: Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll director
Asher Chanan-khan director C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE, COLT NECK NJ 07722
John Neis director 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev officer: Chief Medical Officer 15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355

Cellectar Biosciences (Cellectar Biosciences) Headlines

From GuruFocus

Cellectar Provides a Research and Development Program Summary

By sperokesalga sperokesalga 06-12-2023

Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer

By Value_Insider Value_Insider 11-30-2022